NEW YORK, Aug. 20 (GenomeWeb News) - Roger Perlmutter has been appointed chairman of the Seattle-based Institute for Systems Biology's board of directors, the Institute said Aug. 19.
Perlmutter is executive vice president of R&D at Amgen, and has been a member of ISB's board since it was formed in January 2000.
Prior to Amgen, Perlmutter was an executive vice president at Merck Research Laboratories, and before that, chairman of the department of Immunology at the University of Washington, where he served on the faculty since 1984.
Kleanthis Xanthopoulos has joined the board of directors of Odyssey Thera, a pathway-oriented drug discovery company in San Ramon, Calif., the company said today.
Xanthopoulos is president, CEO, and a co-founder of Anadys Pharmaceuticals. Previously, he was a vice president of genomics & molecular biology at Aurora Biosciences, and a section head at NHGRI, and prior to that, an associate professor at the Karolinska Medical Institute in Stockholm.
David Danley, a retired US Army Colonel, has joined CombiMatrix as the director of homeland security and defense programs, where he will head up efforts to develop products for agents of detection of biological and chemical warfare, the company said Aug. 19.
Danley joins the Squolamie, Wash., subsidiary of Acacia Research after retiring from the armed services earlier this month. Most recently, he was project manager of the Chemical Biological Medical Systems and Joint Vaccine Acquisition Program for the Department of Defense, where he led efforts to for new vaccines against anthrax, smallpox, and other biological agents. Prior to holding this post, Danley was commander of the US Army Center for Environmental Health Research, where he led development and evaluation of sensors for toxic compounds. He was also assistant program manager for the Joint Program Office for Biological Defense.
Mark McCamish has been named chief medical officer and vice president of clinical development at Perlegen Sciences, the Mountain View, Calif., company said Aug. 19.
McCamish was previously global development leader of clinical development at Amgen, where he worked since 1998, and led development and commercialization efforts of drugs in the cardiac, pulmonary and other chronic disease areas. McCamish joined Amgen as clinical studies management team leader, and focused on leptin receptor therapeutics.
Before joining Amgen, McCamish was involved in drug development at Abbott Laboratories for eight years, and before that, served on the faculties of the University of California, Davis, Michigan State University, and Ohio State University.
Kirk Peacock has been appointed chief financial officer of CytRx, the RNAi therapeutics company said Aug. 18.
Peacock replaces Steven Kriegsman, who has served as interim CFO and is also the company's CEO.
Peacock comes to CytRx from DigitalMed, a subsidiary of Tenet Healthcare, where he was chief financial officer and vice president of operations. He has also served as CFO at an internet startup, as controller at Equity Marketing, and as a CPA at Arthur Andersen for seven years.
Hector Gomez has been hired as Chief Medical Officer of DNAPrint Genomics.
Gomez has been DNAPrint board member, and later its chairman, since 2002, and has most recently been president and CEO of Transcend Therapeutics until 1998. His prior positions include a three-year stint as vice president of medical affairs at Vertex Pharmaceuticals, four years as executive director of clinical research at CIBA-GEIGY, and director of clinical research at Merck/MSDRL from 1979 to 1988.